News - Novartis, Markets & Marketing

Filter

Popular Filters

1 to 25 of 74 results

Novartis’ Glivec could lose half patient population in China to generics

Novartis’ Glivec could lose half patient population in China to generics

03-06-2014

Hematologists in China estimate that Glivec (imatinib) from Swiss drug major Novartis will lose nearly…

Blast phase CMLChemistryChinaChronic phase CMLGlivecHealth Medical PharmaHematologyMajorMarkets & MarketingNovartisPharmaceutical

French competition authority investigating Roche and Novartis over Lucentis marketing

10-04-2014

Following similar recent action by the equivalent Italian body, the French competition authority is launching…

AvastinBevacizumabFranceItalyLegalLucentisMarkets & MarketingMedicineNorthern EuropeNovartisOphthalmicsPharmaceuticalPharmacologyRocheUSD

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

28-03-2014

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast…

AfinitorbuparlisibGlaxoSmithKlineHerceptinMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheTykerb

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

07-03-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has decided to award immunosuppressant drug…

Asia-PacificGenericsImmunologicalsMarkets & MarketingNew ZealandNovartisPricingSandozTacrolimus Sandoz

Which place for orphan drugs in the strategy of pharma companies and payers?

27-02-2014

As the 7th Rare Disease Day will be held on February 28, ALCIMED, an innovation and new business consulting…

Markets & MarketingNovartisPharmaceuticalPricingRare diseasesResearchRocheSanofi

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

Modest growth forecast for global CD market

02-12-2013

The global market for cardiovascular disease - comprised of heart failure, myocardial infarction and…

AstraZenecaAZD6140BAY81-8781BayerCardio-vascularLCZ696Markets & MarketingNovartisPharmaceuticalPricingserelaxin

Mylan launches first generic Focalin XR capsules

Mylan launches first generic Focalin XR capsules

18-11-2013

US generics major Mylan has launched dexmethylphenidate hydrochloride extended-release (ER) capsules,…

Focalin XRGenericsMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartis

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs

03-09-2013

More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

New therapies to spur acute myeloid leukemia market growth

27-08-2013

Driven by a boost in new therapies entering the market, as well as an increasing number of acute myeloid…

BiotechnologyCyclacel PharmaceuticalsMarkets & MarketingmidostaurinNovartisOncologyPharmaceuticalsapacitabineSunesis Pharmaceuticalsvosaroxin

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Novartis's new heart failure drug to dominate with $1.9 billion global revenue by 2022, says GlobalData

21-06-2013

Following a launch scheduled for 2015 for the treatment of chronic heart failure (CHF), Swiss drug major…

Cardio-vascularLCZ-696Markets & MarketingNovartisPharmaceutical

Alliance Pharma buys expanded rights to Syntometrine from Novartis

06-06-2013

UK specialty drugmaker Alliance Pharma (AIM: APH) says it has acquired all existing rights to Syntometrine…

Alliance PharmaMarkets & MarketingNovartisPharmaceuticalSyntometrineWomen's Health

Alcon and ThromboGenics Jetrea launched in Denmark and Sweden

28-05-2013

Belgium's ThromboGenics (Euronext Brussels: THR) says that its partner Alcon, the eye care subsidiary…

AlconEuropeJetreaMarkets & MarketingNovartisOphthalmicsPharmaceuticalThromboGenics

CML drug revenue in Japan to grow, despite global decline, says GlobalData

21-05-2013

Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient…

Asia-PacificBristol-Myers SquibbGleevecMarkets & MarketingNovartisOncologyPatentsPharmaceuticalSprycel

pSivida and Alimera's Iluvien debuts in Germany; New data on Novartis' Lucentis

08-05-2013

USA-based pSivida Corp (Nasdaq: PSDV), a leader in developing sustained release, drug delivery products…

Alimera SciencesIluvienLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalpSividaResearch

Novartis charged with paying "kickbacks" to US doctors

29-04-2013

The US Department of Justice announced last Friday (April 26) that the government has filed a second…

LegalMarkets & MarketingNorth AmericaNovartisPharmaceutical

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

1 to 25 of 74 results

Back to top